Results 81 to 90 of about 16,087 (221)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink +2 more
wiley +1 more source
BMC CancerAim This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the ...
Huseyin Ali Ozturk +9 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background The role of histone lactylation in diabetes associated renal fibrosis remains poorly defined. In this study, we investigated the contribution of histone H4 lysine 12 lactylation (H4K12la) to abnormal glycolysis and renal fibrogenesis in diabetic kidney disease (DKD) and evaluated sodium butyrate (NaB) as a potential therapeutic ...
Ping He +10 more
wiley +1 more source
The Effect of Dapagliflozin on Absence Epilepsy in WAG/Rij Rats
Archives of EpilepsyObjective: Epilepsy is the most common chronic brain disease that affects millions of people worldwide. In the present study, we investigated the effects of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which has been recently ...
Hatice Aygün
doaj +1 more source
Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain +15 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake +14 more
wiley +1 more source
SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma
European Journal of Haematology, EarlyView.ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu +6 more
wiley +1 more source
Effects of GLP‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review
The FEBS Journal, EarlyView.This systematic review evaluated 17 studies (12 preclinical and five clinical) on GLP‐1 receptor agonists in type 2 diabetes, demonstrating effects on the gut microbiota and metabolic improvement. The studies showed an increase in Bacteroidetes, Lactobacillus, and Akkermansia, and a reduction in Firmicutes.
Ranicleide Santos Dantas +11 more
wiley +1 more source
BMC MedicineBackground Sunitinib is an orally administered novel multi-targeted therapy for treating tumors especially for gastrointestinal stromal tumors and metastatic renal cell carcinoma (RCC) but associated with cardiovascular toxicity.
Shi-yu Huang +7 more
doaj +1 more source
Journal of Diabetes Investigation, EarlyView.Liraglutide combined with Dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Diabetic cardiomyopathy (DCM) and endothelial dysfunction were established in mice via HFD and STZ injection. The combination therapy of Liraglutide and Dapagliflozin synergistically improved metabolic parameters and attenuated ...
An‐Jun Tan +5 more
wiley +1 more source